GET DAILY SIGNALSCoya Therapeutics (COYA): Analyst Targets Point to +367% Upside
Key Takeaways
- The central stock price target of $15 is the arithmetic mean of six verified, current (2026) analyst price targets, rounded from an underlying average of about $15.33.
- With shares near $3.21, reaching $15 would require an increase of roughly 367% — a very large move by any standard.
- The six analyst targets range from a low of $12 to a high of $18, with all carrying Buy or equivalent ratings.
- The strongest support is the completed enrollment (137 participants) in the Phase 2/3 ALSTARS trial of COYA 302, with topline data expected in early Q2 2027.
- The biggest risks are ongoing cash burn, the absence of an approved product, and the binary nature of the upcoming clinical readout.
- For more detail on this company, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- Readers can also explore Trending AI Robots for AI-driven trading tools and signal-based ideas.
Analyst Price Targets and Consensus View
The $15 central target reflects six current analyst price targets, each attributed to a named firm and reviewed against multiple data providers. They include Roth MKM ($12), Chardan Capital ($14), D. Boral Capital ($15), BTIG ($16), Lake Street ($17), and H.C. Wainwright ($18). The arithmetic mean of these six figures is approximately $15.33, which rounds to a $15 stock price target. The low-to-high range is $12 to $18, and all six firms maintain Buy ratings, with no Holds or Sells in the current group.
The wide range reflects genuine disagreement about how much value to assign to COYA 302 ahead of its pivotal readout. Higher targets emphasize the size of the ALS market opportunity, the FDA's Fast Track designation granted in 2026, and the potential for a substantial re-rating if the trial succeeds. Lower targets apply a deeper discount for execution risk and the long runway before any potential commercialization. None of these figures should be read as a guarantee; they represent research-horizon estimates, not forecasts of near-term trading.
Current Market Position and Path Toward the Target
Shares have fallen sharply over the past year, recently changing hands near $3.21, close to the lower end of a 52-week range that has extended from roughly $2.72 to above $6.60. Moving from $3.21 to $15 implies upside of about 367%, which is a very large required move for a stock whose near-term value is tied to a single pivotal clinical program.
The most likely path toward the target runs through the ALSTARS trial of COYA 302 in ALS. Enrollment is complete at 137 participants, and the company expects topline data from the 24-week double-blind treatment phase in early Q2 2027. Because the company generates only modest collaboration revenue and has no approved product, the share price is heavily dependent on clinical catalysts and financing rather than earnings or cash flow, which remain negative. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Support a Move Toward the Target
- Completed enrollment and a near-term catalyst. Finishing enrollment in ALSTARS removes a key operational overhang and sets a defined timeline for the topline readout.
- Fast Track designation. The FDA granted Fast Track status to COYA 302 for ALS in 2026, which can facilitate more frequent regulatory interaction.
- Unmet medical need. ALS has few effective treatments, so a positive efficacy signal could support a significant revaluation of the pipeline.
- Cash runway past the readout. With about $35.8 million in cash and equivalents at Sept. 30, 2026, management has guided that funds extend into the second half of 2027, beyond the anticipated topline data.
- Pipeline optionality. Programs in frontotemporal dementia (FTD) and earlier-stage Treg and exosome candidates offer additional, if longer-dated, upside.
What Could Prevent the Target From Being Reached
- Clinical risk. A failed or ambiguous ALSTARS readout would likely invalidate the higher price targets and could pressure the shares further.
- Cash burn and dilution. The company reported a $10.6 million net loss in Q3 2026, with research and development spending rising to $8.6 million from $2.9 million a year earlier.
- No commercial revenue base. Third-quarter collaboration revenue was about $234,000, so valuation rests almost entirely on future clinical and regulatory success.
- Delays. The Phase 2 FTD study was already deferred from the second half of 2026 to 2027, illustrating how timelines can shift.
- Competition and binary outcomes. The ALS landscape is crowded, and single-trial biotech stories can reprice sharply in either direction.
Technical Levels and Market Structure
From a technical standpoint, the shares have been in a pronounced downtrend, with the recent $2.72 area acting as an important support zone near the 52-week low. The current price near $3.21 sits above that level but well below prior highs above $6.60. A sustained recovery would first need to reclaim intermediate resistance around the $4 to $5 zone before the much higher analyst targets become relevant. These levels illustrate the scale of the gap between the current price and the $15 central target.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may use different assumptions. For Coya, the pivotal event is the ALSTARS topline readout now expected in early Q2 2027. Investors should also monitor any FTD biomarker data expected in the first quarter of 2027, updates on the open-label extension beginning in November 2026, cash position and any financing announcements, and any changes in analyst ratings or targets as the readout approaches. No definitive forecast is offered here. From what I see, monitoring these elements closely remains essential.
Exploring AI Tools for Trading Insights
In my view, incorporating systematic tools can complement traditional analysis when evaluating names like COYA. Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to monitor stocks and ETFs continuously, generating Buy, Sell, or Hold signals based on market conditions, technical behavior, and AI-driven analysis. These tools help traders discover opportunities, monitor positions, and identify shifting trends more efficiently than manual review alone. I find them useful as part of a broader research process when reviewing clinical-stage companies.
Final Assessment
Whether Coya Therapeutics (COYA) can reach $15 hinges overwhelmingly on the outcome of the ALSTARS trial. The $15 central target — the mean of six current analyst targets ranging from $12 to $18 — sits roughly 367% above the recent price, a very large move that is only plausible, in the view of these analysts, if COYA 302 demonstrates meaningful efficacy in ALS. The completed enrollment, Fast Track designation, and cash runway past the readout are meaningful supports, while clinical failure, dilution, and execution delays are the principal obstacles. The next major signpost is the early Q2 2027 topline readout, and investors should watch that catalyst alongside cash, financing, and any analyst revisions closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
COYA sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for COYA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
COYA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COYA crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for COYA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where COYA's RSI Oscillator exited the oversold zone, 27 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where COYA advanced for three days, in 168 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
COYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (3.498). P/E Ratio (-2.794) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. COYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement